Apricus Biosciences Announces New Data Published in the International Journal of Pharmaceutics Confirming Efficiency of NexACT(R) Drug Delivery Technology
Apricus Biosciences, Inc.
13.10.2011 17:30
---------------------------------------------------------------------------
SAN DIEGO, 2011-10-13 17:30 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today the publication of an article in
the peer-reviewed International Journal of Pharmaceutics, entitled,
'Transdermal and Transbuccal Drug Delivery Systems: Enhancement Using
Iontophoretic and Chemical Approaches,' which confirms the Company's NexACT(r)
technology (DDAIP.HCL) to be the most effective chemical enhancer among three
used in a study for the transbuccal delivery of lidocaine HCL ('LHCL'),
Nicotine hydrogen tartrate ('NHT'), as well as for the transdermal delivery of
diltiazem HCl ('DHCI').
The article appears in the International Journal of Pharmaceutics' on-line
version of its November 2011 issue. The new data discussed is based on research
conducted by, and at, the Ernest Mario School of Pharmacy, Rutgers-The State
University of New Jersey, in Piscataway, NJ. The abstract is available and can
be accessed at the following site:
http://www.sciencedirect.com/science/article/pii/S037851731100874X
In the article, the effects of iontophoresis, the use of a local electric
current to introduce the ions of a drug into the tissues, and a number of
chemical enhancers such as the Company's NexACT(r) (DDAIP.HCI) technology on the
transbuccal and transdermal delivery of three drugs LHCI, NHT and DHCI was
evaluated on porcine skin and buccal tissues in vitro. Specifically, the
article highlights the ability of the NexACT(r) technology to act as an effective
enhancer for the transbuccal delivery of two drugs, LHCI and NHT, and the
transdermal delivery of DHCI. The combination of iontophoresis and the NexACT(r)
technology provided the best overall results for all three drugs and, as a
result, this combined technology may provide new and more effective treatment
approaches upon future research into this area.
Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus
Bio, noted, 'We are very pleased with the success of our NexACT(r) technology
when utilized by independent research labs, and, in particular, by this
additional, promising data showing the effectiveness of our NexACT(r) technology
primarily for the transbuccal delivery of the drugs studied. The data lends
more support to previous work done by both Apricus Bio, as well as other
independent research labs, related to the ability of our proprietary NexACT(r)
drug delivery technology to effectively deliver drugs via the buccal route, and
continues to illustrate a higher penetration rate than that achieved by
currently used chemical enhancers.'
About the NexACT(r) Technology
NexACT(r) utilizes biodegradable excipients, that when incorporated into drug
formulations, has demonstrated the ability to help overcome the body's natural
barrier properties and thereby enable rapid penetration of higher
concentrations of active drug directly through the skin and major biological
membranes, resulting in more effective delivery of therapies. Varying the
concentration of the enhancer allows for local or systemic delivery of active
drug, as desired. NexACT(r) has shown in studies to efficiently enable the
delivery of drugs across different classes and over a wide range of indications
via transdermal, oral, subcutaneous, rectal and buccal routes of
administration.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego-based, revenue-generating, biopharmaceutical company,
has leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the
development and commercialization of such compounds to pharmaceutical and
biotechnology companies worldwide. In addition, the Company is seeking to
monetize its existing Rx Division product pipeline, including its first
product, Vitaros(r), approved in Canada for the treatment of erectile
dysfunction, which is currently expected to be available on the Canadian market
in 2011, as well as compounds in development from pre-clinical through Phase
III, currently focused on Sexual Dysfunction, Oncology, Dermatology,
Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.
The Company is also developing its Consumer Healthcare Division by developing a
number of drugs that utilize the Company's NexACT(r) technology to comply with
the FDA's over-the-counter ('OTC') requirements, be cleared as 510(k) topical
creams that are considered to be medical devices or approved as Abbreviated New
Drug Applications ('ANDAs') as generic drugs. The Company will also seek to
market such drugs through these similar procedures in foreign countries.
For further information on Apricus Bio, visit http://www.apricusbio.com and for
information on its subsidiary please visit www.nexmedusa.com. Information may
also be found at http://twitter.com/apricusbio, and
http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to conduct or part with other
companies to conduct research that demonstrates the effectiveness of its
NexACT(r) drug delivery technology to enhance the delivery of drugs through
various routes of administration such as transdermal, transbuccal among others,
its ability to receive issued patents on its NexACT(r) technology and products,
develop such patented technology into product candidates, have its Rx Division
products and product candidates approved by relevant regulatory authorities and
its Consumer Healthcare Division products either approved or cleared by
relevant regulatory authorities or be in compliance with appropriate regulatory
requirements, to successfully manufacture and commercialize such Rx Division
products along with its Consumer Healthcare Division products and product
candidates and to achieve its other development, commercialization and
financial goals. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the risk
factors set forth in the Company's most recent annual report on Form 10-K,
subsequent quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC's website or without
charge from the Company.
CONTACT: Apricus Biosciences, Inc.
Edward Cox, V.P.
Corporate Development & Investor Relations, Apricus Bio, Inc.
(858) 848-4249
ecox@apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX
13.10.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Apricus Biosciences, Inc.
13.10.2011 17:30
---------------------------------------------------------------------------
SAN DIEGO, 2011-10-13 17:30 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today the publication of an article in
the peer-reviewed International Journal of Pharmaceutics, entitled,
'Transdermal and Transbuccal Drug Delivery Systems: Enhancement Using
Iontophoretic and Chemical Approaches,' which confirms the Company's NexACT(r)
technology (DDAIP.HCL) to be the most effective chemical enhancer among three
used in a study for the transbuccal delivery of lidocaine HCL ('LHCL'),
Nicotine hydrogen tartrate ('NHT'), as well as for the transdermal delivery of
diltiazem HCl ('DHCI').
The article appears in the International Journal of Pharmaceutics' on-line
version of its November 2011 issue. The new data discussed is based on research
conducted by, and at, the Ernest Mario School of Pharmacy, Rutgers-The State
University of New Jersey, in Piscataway, NJ. The abstract is available and can
be accessed at the following site:
http://www.sciencedirect.com/science/article/pii/S037851731100874X
In the article, the effects of iontophoresis, the use of a local electric
current to introduce the ions of a drug into the tissues, and a number of
chemical enhancers such as the Company's NexACT(r) (DDAIP.HCI) technology on the
transbuccal and transdermal delivery of three drugs LHCI, NHT and DHCI was
evaluated on porcine skin and buccal tissues in vitro. Specifically, the
article highlights the ability of the NexACT(r) technology to act as an effective
enhancer for the transbuccal delivery of two drugs, LHCI and NHT, and the
transdermal delivery of DHCI. The combination of iontophoresis and the NexACT(r)
technology provided the best overall results for all three drugs and, as a
result, this combined technology may provide new and more effective treatment
approaches upon future research into this area.
Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus
Bio, noted, 'We are very pleased with the success of our NexACT(r) technology
when utilized by independent research labs, and, in particular, by this
additional, promising data showing the effectiveness of our NexACT(r) technology
primarily for the transbuccal delivery of the drugs studied. The data lends
more support to previous work done by both Apricus Bio, as well as other
independent research labs, related to the ability of our proprietary NexACT(r)
drug delivery technology to effectively deliver drugs via the buccal route, and
continues to illustrate a higher penetration rate than that achieved by
currently used chemical enhancers.'
About the NexACT(r) Technology
NexACT(r) utilizes biodegradable excipients, that when incorporated into drug
formulations, has demonstrated the ability to help overcome the body's natural
barrier properties and thereby enable rapid penetration of higher
concentrations of active drug directly through the skin and major biological
membranes, resulting in more effective delivery of therapies. Varying the
concentration of the enhancer allows for local or systemic delivery of active
drug, as desired. NexACT(r) has shown in studies to efficiently enable the
delivery of drugs across different classes and over a wide range of indications
via transdermal, oral, subcutaneous, rectal and buccal routes of
administration.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego-based, revenue-generating, biopharmaceutical company,
has leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the
development and commercialization of such compounds to pharmaceutical and
biotechnology companies worldwide. In addition, the Company is seeking to
monetize its existing Rx Division product pipeline, including its first
product, Vitaros(r), approved in Canada for the treatment of erectile
dysfunction, which is currently expected to be available on the Canadian market
in 2011, as well as compounds in development from pre-clinical through Phase
III, currently focused on Sexual Dysfunction, Oncology, Dermatology,
Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.
The Company is also developing its Consumer Healthcare Division by developing a
number of drugs that utilize the Company's NexACT(r) technology to comply with
the FDA's over-the-counter ('OTC') requirements, be cleared as 510(k) topical
creams that are considered to be medical devices or approved as Abbreviated New
Drug Applications ('ANDAs') as generic drugs. The Company will also seek to
market such drugs through these similar procedures in foreign countries.
For further information on Apricus Bio, visit http://www.apricusbio.com and for
information on its subsidiary please visit www.nexmedusa.com. Information may
also be found at http://twitter.com/apricusbio, and
http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to conduct or part with other
companies to conduct research that demonstrates the effectiveness of its
NexACT(r) drug delivery technology to enhance the delivery of drugs through
various routes of administration such as transdermal, transbuccal among others,
its ability to receive issued patents on its NexACT(r) technology and products,
develop such patented technology into product candidates, have its Rx Division
products and product candidates approved by relevant regulatory authorities and
its Consumer Healthcare Division products either approved or cleared by
relevant regulatory authorities or be in compliance with appropriate regulatory
requirements, to successfully manufacture and commercialize such Rx Division
products along with its Consumer Healthcare Division products and product
candidates and to achieve its other development, commercialization and
financial goals. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the risk
factors set forth in the Company's most recent annual report on Form 10-K,
subsequent quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC's website or without
charge from the Company.
CONTACT: Apricus Biosciences, Inc.
Edward Cox, V.P.
Corporate Development & Investor Relations, Apricus Bio, Inc.
(858) 848-4249
ecox@apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX
13.10.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------